Wire · opportunities
Experimental ALS treatment slows disease progression by 50% in trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
QRL-201, an experimental antisense oligonucleotide therapy by Quralis, slowed ALS disease progression by 50% at a 10 mg dose in a Phase 1/2 trial and prompted FDA clearance to begin a pivotal Phase 3 trial in the U.S. in 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 16 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
ALS drug development shifts with Quralis clearing FDA to test QRL-201 in a pivotal trial. You in biotech should track this novel genetic therapy as it opens rare disease markets earlier than usual.
◆ Coverage
3 sources · first reported 16 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics